Compare · IMGO vs NVO
IMGO vs NVO
Side-by-side comparison of Imago BioSciences Inc. (IMGO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMGO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $184.18B.
- NVO has hit the wire 9 times in the past 4 weeks while IMGO has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 6 for IMGO).
- Company
- Imago BioSciences Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- -
- $184.18B
- 1M return
- -
- +7.16%
- 1Y return
- -
- -14.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 9
- Recent ratings
- 6
- 25
Imago BioSciences Inc.
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IMGO
- Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies
- SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)
- SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)
- SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)
- SEC Form 15-12G filed by Imago BioSciences Inc.
- SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)
- SEC Form EFFECT filed by Imago BioSciences Inc.
- SEC Form SC 13D/A filed by Imago BioSciences Inc. (Amendment)
- SEC Form 4 filed by Keating Laurie
- SEC Form 4: Tapper Amy E. closing all direct ownership in the company
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S